Treating through of drug-associated exanthem in drug allergy management: current evidence and clinical aspects.

Abstract

In the setting of an acute cutaneous adverse drug reaction (CADR) there is increasing interest in selected phenotypes and hosts to continue drug therapy, especially in settings where there are limited therapeutic options. This concept of "treating through", defined as the continued use of a drug in the setting of, in particular maculopapular exanthema (MPE), potentially avoids unnecessary drug discontinuation. A review of the recent literature, historical viewpoints and expert opinion are provided within to form recommendations and algorithms for a "treating through" approach.